HealthEquity, Inc. (NASDAQ: HQY) saw a sharp increase in short-term interest in December. As of December 15, there was overdraft interest totaling 3,730,000 shares, an increase of 22.3% from the total of 3,050,000 shares as of November 30. Based on an average trading volume of 743,300 shares, the short-term interest ratio is currently 5.0 days. About 4.6% of stocks are sold short.
Actions of NASDAQ HQY traded at $ 0.89 in Friday’s session, reaching $ 45.40. The company’s 657,836 shares traded hands, compared to its average volume of 771,207. HealthEquity has a one-year low at $ 36.81 and a one-year high at $ 93.32. The company has a 50-day mobile average price of $ 54.30 and a 200-day mobile average price of $ 64.40. The company has a market cap of $ 3.80 billion, a P / E ratio of -654.76, a P / E / G ratio of 3.24 and a beta of 1.21. The company has a rapid ratio of 7.14, a current ratio of 7.14 and a debt ratio of 0.49.
HealthEquity (NASDAQ: HQY) last announced its quarterly earnings data on Monday, December 6. The company reported earnings per share (EPS) of $ 0.35 for the quarter, hitting Thomson Reuters’ consensus estimate of $ 0.35. HealthEquity had a negative net margin of 0.82% and a positive return on equity of 4.60%. The company posted revenue of $ 180.00 million in the quarter, against analysts’ expectations of $ 185.44 million. During the same period of the previous year, the company achieved EPS of $ 0.30. The company’s quarterly revenue increased 0.3% from the same quarter last year. Research analysts predict that HealthEquity will post 0.83 EPS for the current fiscal year.
In addition, director Stuart B. Parker bought 25,000 shares of HealthEquity in a transaction dated Thursday, December 9. The stock was purchased at an average cost of $ 42.82 per share, for a total transaction of $ 1,070,500.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP William Robert Otten sold 1,850 shares of HealthEquity in a trade that took place on Monday, November 1. The shares were sold at an average price of $ 66.42, for a total trade of $ 122,877.00. Disclosure of this sale can be found here. 2.80% of the shares are currently held by insiders of the company.
Several hedge funds and other institutional investors recently changed their positions in HQY. Advisor Group Holdings Inc. increased its holdings of HealthEquity shares by 29.4% in the second quarter. Advisor Group Holdings Inc. now owns 5,559 shares of the company valued at $ 447,000 after acquiring 1,263 additional shares during the last quarter. Envestnet Asset Management Inc. increased its holdings of HealthEquity shares by 35.6% in the second quarter. Envestnet Asset Management Inc. now owns 39,989 shares of the company valued at $ 3,218,000 after acquiring an additional 10,504 shares during the last quarter. Teacher Retirement System of Texas increased its equity stake in HealthEquity by 17.5% during the 2nd quarter. Teacher Retirement System of Texas now owns 10,116 shares of the company valued at $ 814,000 after acquiring 1,504 additional shares during the last quarter. The Swiss National Bank increased its stake in HealthEquity shares by 3.1% in the second quarter. The Swiss National Bank now owns 181,100 shares of the company valued at $ 14,575,000 after acquiring an additional 5,500 shares in the last quarter. Finally, HighTower Advisors LLC increased its stake in HealthEquity shares by 0.7% during the 2nd quarter. HighTower Advisors LLC now owns 83,940 shares of the company valued at $ 6,758,000 after acquiring 543 additional shares during the last quarter. 99.48% of the shares are held by institutional investors.
A number of brokerage firms have recently weighed in on HQY. TheStreet reduced HealthEquity’s shares from a “c” rating to a “d +” rating in a Tuesday, December 7 research note. Royal Bank of Canada lowered its price target for HealthEquity shares from $ 87.00 to $ 70.00 and established an “outperformance” rating for the company in a research note on Tuesday, December 7. JPMorgan Chase & Co. lowered its price target for HealthEquity shares from $ 82.00 to $ 56.00 and set an “overweight” rating for the company in a research note on Tuesday, December 21. Deutsche Bank Aktiengesellschaft lowered its price target on HealthEquity shares from $ 75.00 to $ 52.00 and set a “buy” rating for the company in a research note on Wednesday, December 8. Finally, Raymond James downgraded HealthEquity shares from a “strong buy” rating to an “outperformance” rating and lowered his price target for the stock from $ 90.00 to $ 70.00 in a year. Tuesday, December 7 research note. Two research analysts rated the stock with a conservation rating and nine gave the stock a buy rating. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $ 74.00.
HealthEquity Company Profile
HealthEquity, Inc. provides a range of solutions for managing health care accounts. The firm offers its solutions to employers, health plans, brokers, consultants and financial advisers. Its services include HAS, FSA, HRA, DCRA, 401 (k), Commuter, COBRA and HIA. It also offers products such as the Health Savings and Spending Platform, Health Savings Accounts, Investment Advisory Services, Repayment Terms and Health Incentives.
Featured article: Capital gains
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in HealthEquity now?
Before you consider HealthEquity, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes over … and HealthEquity was not on the list.
While HealthEquity currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here